JNJ240719C172500
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson reports Q2 2024 results
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.RBC Capital Markets anticipates a favorable second-quarter
Johnson & Johnson Shares Trade at Fair Value After Q2 Results, 2024 Guidance, Morgan Stanley Says
Johnson & Johnson's (JNJ) shares are trading at fair value based on a sum-of-the-parts analysis after Q2 results and 2024 revenue guidance was mostly in line with expectations, Morgan Stanley said
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday.The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The
Johnson & Johnson Price Target Cut to $185.00/Share From $195.00 by TD Cowen
Johnson & Johnson Price Target Cut to $185.00/Share From $195.00 by TD
Johnson & Johnson Is Maintained at Buy by TD Cowen
Johnson & Johnson Is Maintained at Buy by TD
Express News | TD Cowen Maintains Buy on Johnson & Johnson, Lowers Price Target to $185
Med-tech and Healthcare Stocks With Upside During 2Q Earnings - Baird
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an
Express News | RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
Company News for Jul 18, 2024
Argus Research Initiates Johnson & Johnson(JNJ.US) With Buy Rating
Argus Research analyst David Toung initiates coverage on $Johnson & Johnson(JNJ.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 63.1% and a total average return
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $169
Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $169.According to TipRanks data, the analyst has a success rate of 66.0
BofA Securities Initiates Johnson & Johnson(JNJ.US) With Hold Rating, Announces Target Price $170
BofA Securities analyst Alexandria Hammond initiates coverage on $Johnson & Johnson(JNJ.US)$ with a hold rating, and sets the target price at $170.According to TipRanks data, the analyst has a
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $160 to $185
On Jul 18, major Wall Street analysts update their ratings for $Johnson & Johnson(JNJ.US)$, with price targets ranging from $160 to $185.Morgan Stanley analyst Terence Flynn maintains with a hold
Johnson & Johnson (JNJ) Gets a Buy From RBC Capital
Johnson & Johnson Is Maintained at Equal-Weight by Morgan Stanley
Johnson & Johnson Is Maintained at Equal-Weight by Morgan
Johnson & Johnson Price Target Raised to $169.00/Share From $167.00 by Morgan Stanley
Johnson & Johnson Price Target Raised to $169.00/Share From $167.00 by Morgan
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $167, Maintains Equalweight Rating
Johnson & Johnson (JNJ) has an average rating of outperform and price targets ranging from $155 to $215, according to analysts by Capital IQ.Price: 156.61, Change: +0.03, Percent Change: +0.02
Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $169
Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price target from $167 to $169.